
Recombinant antibodies are synthetic proteins created by combining different parts of antibody molecules from different sources. These molecules can be customized to target specific antigens, making them a powerful tool in the fields of medicine and biotechnology.
Traditional antibodies are made by the body's immune system to identify and neutralize foreign substances like bacteria or viruses. Recombinant antibodies, on the other hand, are designed in a laboratory to target specific molecules, such as those found on the surface of cancer cells.
One of the main advantages of recombinant antibodies is their ability to be produced on a large scale, making them useful in the development of diagnostic tools and therapeutic drugs. By leveraging mammalian recombinant protein expression, these antibodies can be produced with proper folding and post-translational modifications, ensuring their functionality for therapeutic and research applications. At Biointron, we specialize in creating high-quality recombinant antibodies through our fast and efficient platform. Our recombinant protein expression service supports the production of these antibodies with precision and scalability, ensuring optimal quality and efficiency. Our team of experts can create recombinant antibodies from scratch, starting with gene synthesis all the way to protein purification. This service is designed to accelerate your research and drug discovery projects with high-quality recombinant antibodies at an economical price.
Our team of experts can create recombinant antibodies from scratch, starting with gene synthesis all the way to protein purification. Our service is designed to accelerate your research and drug discovery projects with high-quality recombinant antibodies at an economical price.
To learn more about how our recombinant antibody service can benefit your research, visit our website at https://www.biointron.com/recombinant-protein-expression/recombinant-protein-expression-in-mammalian-cells.html
Antibody discovery has traditionally relied on selecting clones based on target ……
The Society for Immunotherapy of Cancer (SITC) 2025 conference was held in Natio……
A VHH library is a collection of variable domains of heavy-chain antibodies (VHH……
Biointron is proud to announce the launch of the Biointron Quarterly Travel Gran……
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.



